Organon [OGN] vs Medicus Pharma [MDPLD] Detailed Stock Comparison

Organon & Co.

NYSE
Loading...

Medicus Pharma Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Organon & Co. wins in 10 metrics, Medicus Pharma Ltd. wins in 1 metrics, with 1 ties. Organon & Co. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Organon & Co. Medicus Pharma Ltd. Better
P/E Ratio (TTM) 11.94 -1.47 Organon & Co.
Price-to-Book Ratio 2.98 3.90 Organon & Co.
Debt-to-Equity Ratio 1,170.21 0.10 Medicus Pharma Ltd.
PEG Ratio -0.04 N/A N/A
EV/EBITDA 6.33 0.00 Tie
Profit Margin (TTM) 3.01% 0.00% Organon & Co.
Operating Margin (TTM) 16.19% 0.00% Organon & Co.
EBITDA Margin (TTM) 16.19% N/A N/A
Return on Equity 30.56% -841.91% Organon & Co.
Return on Assets (TTM) 6.22% -358.37% Organon & Co.
Free Cash Flow (TTM) $384.00M $-4.16M Organon & Co.
Dividend Yield 1.10% N/A N/A
1-Year Return 33.86% N/A N/A
Price-to-Sales Ratio (TTM) 0.36 N/A N/A
Enterprise Value $10.46B $0 Organon & Co.
EV/Revenue Ratio 1.68 N/A N/A
Gross Profit Margin (TTM) 49.17% N/A N/A
Revenue per Share (TTM) $24 $0 Organon & Co.
Earnings per Share (Diluted) $0.72 $-2.54 Organon & Co.
Beta (Stock Volatility) 0.64 N/A N/A
Short % of Float 11.33% N/A N/A

Organon & Co. vs Medicus Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

OGN
MDPLD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Organon & Co.0.00%0.37%0.30%111.99%91.45%85.64%
Medicus Pharma Ltd.1.78%0.00%0.00%0.00%0.00%0.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Organon & Co.33.86%-35.72%-55.17%-59.58%-59.58%-59.58%
Medicus Pharma Ltd.N/AN/AN/AN/AN/AN/A

Performance & Financial Health Analysis: Organon & Co. vs Medicus Pharma Ltd.

MetricOGNMDPLD
Market Information
Market Cap i$2.24BN/A
Market Cap CategoryMid capN/A
10 Day Avg. Volume i11,076,16820,091
90 Day Avg. Volume i6,348,98936,712
Last Close$13.44$2.86
52 Week Range$5.69 - $13.49$1.80 - $6.00
% from 52W High-0.37%-52.33%
All-Time High$39.47 (Feb 28, 2022)$3.00 (Jan 24, 2025)
% from All-Time High-65.95%-4.67%
Growth Metrics
Quarterly Revenue Growth-0.05%N/A
Quarterly Earnings Growth-0.05%N/A
Financial Health
Profit Margin (TTM) i0.03%0.00%
Operating Margin (TTM) i0.16%0.00%
Return on Equity (TTM) i0.31%-8.42%
Debt to Equity (MRQ) i1,170.210.10
Cash & Liquidity
Book Value per Share (MRQ)$2.89$0.73
Cash per Share (MRQ)$2.21N/A
Operating Cash Flow (TTM) i$700.00M$-4,987,008
Levered Free Cash Flow (TTM) i$190.12M$-6,784,140
Dividends
Last 12-Month Dividend Yield i1.10%N/A
Last 12-Month Dividend i$0.08N/A

Valuation & Enterprise Metrics Analysis: Organon & Co. vs Medicus Pharma Ltd.

MetricOGN (Apr 24, 2026)MDPLD (Mar 31, 2025)
Price Ratios
P/E Ratio (TTM) i11.94-1.47
Forward P/E i2.33N/A
PEG Ratio i-0.04N/A
Price to Sales (TTM) i0.36N/A
Price to Book (MRQ) i2.983.90
Market Capitalization
Market Capitalization i$2.24B$22.45M
Enterprise Value i$10.46B$0
Enterprise Value Metrics
Enterprise to Revenue i1.68N/A
Enterprise to EBITDA i6.330.00
Risk & Other Metrics
Beta i0.64N/A
Book Value per Share (MRQ) i$2.89$0.73

Financial Statements Comparison: Organon & Co. vs Medicus Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricOGN (2025)MDPLD (2023)
Revenue/Sales i6.22B0
Cost of Goods Sold i2.90BN/A
COGS % of Revenue i46.7%-
Gross Profit i3.31BN/A
Gross Margin i53.3%-
Research & Development i366.00M193,578
Operating Income (EBIT) i1.23B-3.01M
Operating Margin i19.7%-
EBITDA i1.71B-6.72M
EBITDA Margin i27.4%-
Pre-Tax Income i425.00M-6.78M
Pre-Tax Income % of Revenue i6.8%-
Income Tax i238.00MN/A
Income Tax % of Revenue i3.8%-
Net Income (Profit) i187.00M-6.78M
Profit Margin i3.0%-

Balance Sheet & Liquidity Metrics

MetricOGN (2025)MDPLD (2023)
Cash & Equivalents i574.00M1.72M
Total Current Assets i4.35B1.89M
Total Current Assets % of Revenue i70.0%-
Total Current Liabilities i2.39B1.09M
Total Current Liabilities % of Revenue i38.4%-
Long-Term Debt i8.63BN/A
Long-Term Debt % of Revenue i138.8%-
Total Shareholders Equity i752.00M805,800
Retained Earnings i1.11B-19.18M
Retained Earnings % of Revenue i17.8%-
Property, Plant & Equipment i0N/A

Cash Flow Statement Comparison

MetricOGN (2025)MDPLD (2023)
Operating Cash Flow i687.00M-4.99M
Operating Cash Flow % of Revenue i11.1%-
Capital Expenditures i1.00MN/A
Free Cash Flow i384.00M-4.16M
FCF Margin i6.2%-
Debt Repayment i-1.51BN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricOGNMDPLD
Shares Short i22.13MN/A
Short Ratio i6.50N/A
Short % of Float i11.33%N/A
Shares Outstanding i260.32M8.08M
Float Shares i258.71MN/A
% Held by Insiders i0.33%55.81%
% Held by Institutions i77.57%0.00%
% Held by Public i22.10%44.19%

Dividend Analysis & Yield Comparison: Organon & Co. vs Medicus Pharma Ltd.

MetricOGNMDPLD
Last 12-Month Dividend i$0.08N/A
Last 12-Month Dividend Yield i1.10%N/A
3-Year Avg Annual Dividend i$0.77N/A
3-Year Avg Dividend Yield i1.16%N/A
3-Year Total Dividends i$2.32N/A
Ex-Dividend DateFeb 23, 2026N/A